A5035087671- HIV Research and Treatment
- HIV/AIDS Research and Interventions
- Immune Cell Function and Interaction
- Phagocytosis and Immune Regulation
- Herpesvirus Infections and Treatments
- HIV/AIDS drug development and treatment
- Sex work and related issues
- Cytomegalovirus and herpesvirus research
- Immune responses and vaccinations
- Systemic Lupus Erythematosus Research
Frederick National Laboratory for Cancer Research
2022-2024
Pancreatic Cancer Action Network
2019-2021
The rebound competent viral reservoir (RCVR)–virus that persists during antiretroviral treatment (ART) and can reignite systemic infection when is stopped–is the primary barrier to eradicating HIV. We used time initiation of ART rhesus macaques (RMs) after intravenous challenge with barcoded SIVmac239 as a means elucidate dynamics RCVR establishment in groups RMs by creating multi-log range pre-ART loads then assessed time-to-rebound reactivation rates resulting from discontinuation one...
The strain 68-1 rhesus cytomegalovirus (RhCMV)–based vaccine for simian immunodeficiency virus (SIV) can stringently protect macaques (RMs) from SIV challenge by arresting viral replication early in primary infection. This elicits unconventional SIV-specific CD8 + T cells that recognize epitopes presented major histocompatibility complex (MHC)–II and MHC-E instead of MHC-Ia. Although RhCMV/SIV vaccines based on strains only elicit MHC-II– and/or MHC-Ia–restricted do not against SIV, it...
Reduction/elimination of HIV-1 reservoirs that persist despite combination antiretroviral therapy (cART) will likely require induction viral expression by residual infected cells and enhanced clearance these cells. TLR7 agonists have potential to mediate activities. We evaluated immunologic virologic effects repeated doses the agonist GS-9620 in SIV-infected rhesus macaques receiving cART, which was initiated at 13 days after infection continued for 75 weeks prior administration. During...
The effectiveness of virus-specific strategies, including administered HIV-specific mAbs, to target cells that persistently harbor latent, rebound-competent HIV genomes during combination antiretroviral therapy (cART) has been limited by inefficient induction viral protein expression. To examine antibody-mediated reservoir targeting without a need for induction, we used an anti-CD4 mAb deplete both infected and uninfected CD4+ T cells. Ten rhesus macaques with barcoded SIVmac239M received...
Persistence of the rebound-competent viral reservoir (RCVR) within CD4 + T cell compartment people living with HIV remains a major barrier to cure. Here, we determined effects pan-lymphocyte-depleting monoclonal antibody (mAb) alemtuzumab on RCVR in SIVmac239-infected rhesus macaques (RM) receiving antiretroviral therapy (ART). Alemtuzumab administered during chronic ART or at time initiation induced >95% depletion circulating cells peripheral blood and substantial lymph nodes. However,...